+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • ID: 5240465
  • Report
  • January 2021
  • Region: Global
  • 550 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 4BIO Capital
  • Boehringer Ingelheim
  • Exegenesis Bio
  • Intrexon
  • Novo Nordisk
  • Seraph Research Institute

Overview

Over time, several gene therapies have been developed for the treatment of both simple (single defect) and complex (multiple defects) genetic disorders. In fact, there are 10 approved gene therapies (recent examples include Zolgensma®, Zynteglo™ and Collategene®), till date, and more than a thousand product candidates being evaluated in clinical trials, worldwide. Considering the current pace of research and product development activity in this field, experts believe that the number of clinical research initiatives involving gene therapies are likely to grow by 17% annually. In this context, the USFDA released a notification, mentioning that it now expects to receive twice as many gene therapy applications each year, starting 2020. Despite the ongoing pandemic, it is worth highlighting that gene therapy companies raised approximately USD 5.5 billion in capital investments, in 2020 alone. This is indicative of the promising therapeutic potential of this emerging class of pharmacological interventions, which has led investors to bet heavily on the success of different gene therapy candidates in the long term.

Several technology platforms are currently available for discovery and development of various types of gene therapies. In fact, advances in bioanalytical methods (such as genome sequencing), and genome editing and manipulation technologies (such as molecular switches), have enabled the development of novel therapy development tools/platforms. In fact, technology licensing is a lucrative source of income for stakeholders in this industry, particularly for those with proprietary gene editing platforms. Given the growing demand for interventions that focus on the amelioration of the underlying (genetic) causes of diseases, it is expected that the gene therapy pipeline will continue to steadily expand. Moreover, promising results from ongoing clinical research initiatives are likely to bring in more investments to support therapy product development initiatives in this domain. Therefore, we are led to believe that the global gene therapy market is poised to witness significant growth in the foreseen future.

Scope of the Report

The “Gene Therapy Market (4th Edition) by Therapeutic Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy and Others), Type of Gene Therapy (Ex vivo and In vivo), Type of Vectors used (Adeno Associated Virus, Adenovirus, Herpes Simplex Virus, Lentivirus, Plasmid DNA, Retrovirus and Others), Target Therapeutic Areas (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Genetic Disorders, Hematological Disorders, Metabolic Disorders, Muscle-related Diseases, Oncological Disorders, Ophthalmic Diseases and Others), Route of Administration (Intraarticular, Intracerebellar, Intradermal, Intramuscular, Intratumoral, Intravenous, Intravesical, Intravitreal, Subretinal and Others), and Key Geographical Regions (US, EU5 and rest of the world): Industry Trends and Global Forecasts, 2020-2030” report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, immunotherapies and gene editing therapies. The study also features an elaborate discussion on the future potential of this evolving market.

Amongst other elements, the report features:

  • A detailed review of the overall market landscape of gene therapies and gene editing therapies, including information on phase of development (marketed, clinical, preclinical and discovery) of pipeline candidates, key therapeutic areas (autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, liver diseases, metabolic disorders, muscle-related diseases, nervous system disorders, oncological disorders, ophthalmic diseases and others), target disease indication(s), type of vector used, type of gene, therapeutic approach (gene augmentation, oncolytic viral therapy and others), type of gene therapy (ex vivo and in vivo), route of administration and special drug designation(s) awarded (if any).
  • A detailed review of the players engaged in the development of gene therapies, along with information on their year of establishment, company size, location of headquarters, regional landscape and key players engaged in this domain.
  • An elaborate discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages and limitations of currently available gene delivery vectors.
  • A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Hong Kong, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies. 
  • Detailed profiles of marketed and late stage (phase II/III and above) gene therapies, including development timeline of the therapy, information on the current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, as well as details related to the developer company.
  • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers across different stages of therapy development, including prior to drug launch, at/during drug launch and post-marketing. 
  • A review of the various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were/are being used for the development of four or more products/product candidates. 
  • An in-depth analysis of various patents that have been filed/granted related to gene therapies and gene editing therapies, since 2016. The analysis assesses several relevant parameters associated with the patents, including type of patent (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry players (in terms of the number of patents filed/granted), and patent valuation.
  • A detailed analysis of the various mergers and acquisitions that have taken place within this domain, during the period 2015-2020, based on several relevant parameters, such as year of agreement, type of deal, geographical location of the companies involved, key value drivers, highest phase of development of the acquired company’ product and target therapeutic area.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, between 2015-2020, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings.
  • A detailed geographical clinical trial analysis of completed, ongoing and planned studies of numerous gene therapies, based on various relevant parameters, such as trial registration year, trial status, trial phase, target therapeutic area, geography, type of sponsor, prominent treatment sites and enrolled patient population.
  • An analysis of the various factors that are likely to influence the pricing of gene therapies, featuring different models/approaches that may be adopted by manufacturers to decide the prices of these therapies.
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio. 
  • An informed estimate of the annual demand for gene therapies, taking into account the marketed gene-based therapies and clinical studies evaluating gene therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A case study on the prevalent and emerging trends related to vector manufacturing, along with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors.
  • A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with gene therapies, for the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] therapeutic approach (gene augmentation, oncolytic viral therapy, immunotherapy and others), [B] type of gene therapy (ex vivo and in vivo), [C] type of vectors used (adeno associated virus, adenovirus, herpes simplex virus, lentivirus, plasmid DNA, retrovirus and others), [D] target therapeutic areas (autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases and others), [E] route of administration (intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal and others), and [F] key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Adam Rogers (CEO, Hemera Biosciences)
  • Al Hawkins (CEO, Milo Biotechnology)
  • Buel Dan Rodgers (Founder & CEO, AAVogen)
  • Christopher Reinhard (CEO and Chairman, Gene Therapeutics (previously known as Cardium Therapeutics))
  • Michael Triplett (CEO, Myonexus Therapeutics)
  • Robert Jan Lamers (CEO, Arthrogen)
  • Ryo Kubota (CEO, Chairman & President, Acucela)
  • Tom Wilton (CBO, LogicBio Therapeutics)
  • Jeffrey Hung (CCO, Vigene Biosciences)
  • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
  • Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
  • Molly Cameron (Corporate Communications Manager, Orchard Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players engaged in the development of gene therapies? 
  • How many gene therapy candidates are present in the current development pipeline? Which key disease indications are targeted by such products? 
  • Which types of vectors are most commonly used for effective delivery of gene therapies?
  • What are the key regulatory requirements for gene therapy approval, across various geographies?
  • Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of development?
  • What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?
  • What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
  • Who are the key CMOs/CDMOs engaged in supplying viral/plasmid vectors for gene therapy development?
  • What are the key value drivers of the merger and acquisition activity in the gene therapy industry?
  • Who are the key stakeholders that have actively made investments in the gene therapy domain?
  • Which are the most active trial sites (in terms of number of clinical studies being conducted) related to this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4BIO Capital
  • Boehringer Ingelheim
  • Exegenesis Bio
  • Intrexon
  • Novo Nordisk
  • Seraph Research Institute

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Evolution of Gene Therapies
3.3. Classification of Gene Therapies
3.3.1. Somatic and Germline Therapies
3.3.2. Ex Vivo and In Vivo Therapies
3.4. Routes of Administration
3.5. Mechanism of Action of Gene Therapies
3.6. Overview of the Basic Concepts of Gene Editing
3.6.1. Evolution of Genome Editing 
3.6.2. Applications of Genome Editing
3.6.3. Genome Editing Techniques
3.7. Advantages and Disadvantages of Gene Therapies
3.8. Ethical and Social Concerns Related to Gene Therapies
3.9. Constraints and Challenges Related to Gene Therapies
3.9.1. Therapy Development Concerns
3.9.2. Manufacturing Concerns
3.9.3. Commercial Viability Concerns

4. GENE DELIVERY VECTORS
4.1. Chapter Overview
4.2. Viral and Non-Viral Methods of Gene Transfer
4.3. Viral Vectors for Genetically Modified Therapies
4.4. Types of Viral Vectors
4.4.1. Adeno-associated Viral Vectors
4.4.1.1. Overview
4.4.1.2. Design and Manufacturing
4.4.1.3. Advantages
4.4.1.4. Limitations
4.4.2. Adenoviral Vectors
4.4.2.1. Overview
4.4.2.2. Design and Manufacturing
4.4.2.3. Advantages
4.4.2.4. Limitations
4.4.3. Lentiviral Vectors
4.4.3.1. Overview
4.4.3.2. Design and Manufacturing
4.4.3.3. Advantages
4.4.3.4. Limitations
4.4.4. Retroviral Vectors
4.4.4.1. Overview
4.4.4.2. Design and Manufacturing
4.4.4.3. Advantages
4.4.4.4. Limitations
4.4.5. Other Viral Vectors
4.4.5.1. Alphavirus
4.4.5.2. Foamy Virus
4.4.5.3. Herpes Simplex Virus
4.4.5.4. Sendai Virus
4.4.5.5. Simian Virus
4.4.5.6. Vaccinia Virus
4.5. Types of Non-Viral Vectors
4.5.1. Plasmid DNA
4.5.2. Liposomes, Lipoplexes and Polyplexes
4.5.3. Oligonucleotides
4.5.4. Other Non-Viral Vectors
4.5.5. Gene Delivery Using Non-Viral Vectors
4.5.5.1. Biolistic Methods
4.5.5.2. Electroporation
4.5.5.3. Receptor Mediated Gene Delivery
4.5.5.4. Gene Activated Matrix (GAM)

5. REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. The Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific
5.4.1. Chinese Scenario
5.4.2. Japanese Scenario
5.4.3. South Korean Scenario
5.4.4. Australian Scenario
5.4.5. Hong Kong Scenario
5.5. Reimbursement Scenario
5.5.1. Challenges Related to Reimbursement
5.6. Commonly Offered Payment Models for Gene Therapies

6. MARKET OVERVIEW
6.1. Chapter Overview
6.1.1. Analysis by Phase of Development of Gene Therapy
6.2. Gene Therapy Market: Clinical and Commercial Pipeline
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Therapeutic Area
6.2.3. Analysis by Type of Vector Used
6.2.4. Analysis by Type of Gene 
6.2.5. Analysis by Therapeutic Approach
6.2.6. Analysis by Type of Gene Therapy 
6.2.7. Analysis by Route of Administration
6.3. Gene Therapy Market: Early Stage Pipeline
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Area
6.3.3. Analysis by Type of Vector Used
6.3.4. Analysis by Type of Gene
6.3.5. Analysis by Therapeutic Approach
6.3.6. Analysis by Type of Gene Therapy
6.4. Gene Therapy Candidates: Special Designations 
6.4.1. Analysis by Special Designation(s) Awarded
6.5. Grid Representation: Analysis by Phase of Development, Therapeutic Area and Therapeutic Approach

7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Gene Therapy Market: List of Developers
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Geography
7.3. Key Players: Analysis by Number of Product Candidates

8. MARKETED GENE THERAPIES
8.1. Chapter Overview
8.2. Gendicine® (Shenzhen Sibiono GeneTech)
8.2.1. Company Overview
8.2.2. Development Timeline
8.2.3. Mechanism of Action and Vectors Used
8.2.4. Target Indication(s)
8.2.5. Current Status of Development
8.2.6. Manufacturing, Dosage and Sales
8.3. Oncorine® (Shanghai Sunway Biotech)
8.3.1. Company Overview
8.3.2. Development Timeline
8.3.3. Mechanism of Action and Vectors Used
8.3.4. Target Indication(s)
8.3.5. Current Status of Development
8.3.6. Manufacturing, Dosage and Sales
8.4. Rexin-G® (Epeius Biotechnologies)
8.4.1. Company Overview
8.4.2. Development Timeline
8.4.3. Mechanism of Action and Vector Used
8.4.4. Target Indication(s)
8.4.5. Current Status of Development
8.4.6. Manufacturing, Dosage and Sales
8.5. Neovasculgen® (Human Stem Cells Institute)
8.5.1. Company Overview
8.5.2. Development Timeline 
8.5.3. Mechanism of Action and Vectors Used
8.5.4. Target Indication(s)
8.5.5. Current Status of Development
8.5.6. Manufacturing, Dosage and Sales
8.6. Imlygic® (Amgen)
8.6.1. Company Overview
8.6.2. Development Timeline 
8.6.3. Mechanism of Action and Vectors Used
8.6.4. Target Indication(s)
8.6.5. Current Status of Development
8.6.6. Manufacturing, Dosage and Sales
8.7. Strimvelis® (Orchard Therapeutics)
8.7.1. Company Overview
8.7.2. Development Timeline 
8.7.3. Mechanism of Action and Vectors Used
8.7.4. Target Indication(s)
8.7.5. Current Status of Development
8.7.6. Manufacturing, Dosage and Sales
8.8. Luxturna™ (Spark Therapeutics)
8.8.1. Company Overview
8.8.2. Development Timeline 
8.8.3. Mechanism of Action and Vector Used
8.8.4. Target Indication(s)
8.8.5. Current Status of Development
8.8.6. Manufacturing, Dosage and Sales
8.9. Zolgensma™ (Novartis Gene Therapies)
8.9.1. Company Overview
8.9.2. Development Timeline 
8.9.3. Mechanism of Action and Vector Used
8.9.4. Target Indication(s)
8.9.5. Current Status of Development
8.9.6. Manufacturing, Dosage and Sales
8.10. Collategene® (AnGes)
8.10.1. Company Overview
8.10.2. Development Timeline 
8.10.3. Mechanism of Action and Vector Used
8.10.4. Target Indication(s)
8.10.5. Current Status of Development
8.10.6. Manufacturing, Dosage and Sales
8.11. Zyntelgo™ (bluebird bio)
8.11.1. Company Overview
8.11.2. Development Timeline 
8.11.3. Mechanism of Action and Vector Used
8.11.4. Target Indication(s)
8.11.5. Current Status of Development
8.11.6. Manufacturing, Dosage and Sales

9. KEY COMMERCIALIZATION STRATEGIES
9.1. Chapter Overview
9.2. Successful Drug Launch Strategy: Framework
9.3. Successful Drug Launch Strategy: Product Differentiation
9.4. Commonly Adopted Commercialization Strategies based on Phase of Development of Product
9.5. List of Currently Approved Gene Therapies
9.6. Key Commercialization Strategies Adopted by Companies Focused on Gene Therapy
9.6.1. Strategies Adopted Before Therapy Approval 
9.6.2. Strategies Adopted During / Post Therapy Approval 
9.7. Concluding Remarks

10. LATE STAGE (PHASE II/III AND ABOVE) GENE THERAPIES
10.1. Chapter Overview
10.2. GS010
10.3. PTC-AADC
10.4. BMN 270
10.5. rAd-IFN/Syn3
10.6. TAVO™
10.7. OTL-200
10.8. EB-101
10.9. ProstAtak®
10.10. BIIB111
10.11. LentiGlobin BB305®
10.12. Lenti-D™
10.13. FCX-007
10.14. CG0070
10.15. Vigil®
10.16. VM202
10.17. VGX-3100
10.18. Invossa™
10.19. KB103
10.20. PF-06939926
10.21. PF-06838435
10.22. PF-07055480
10.23. SPK-8011
10.24. AMT-061
10.25. VB-111
10.26. OTL-101
10.27. BIIB112
10.28. FLT180a
10.29. LYS-SAF302
10.30. NFS-01
10.31. OTL-103

11. EMERGING TECHNOLOGIES
11.1. Chapter Overview
11.2. Gene Editing Technologies
11.2.1. Overview
11.2.2. Applications
11.3. Emerging Gene Editing Platforms
11.3.1. CRISPR / Cas9 System
11.3.2. TALENs
11.3.3. megaTAL
11.3.4. Zinc Finger Nuclease
11.4. Gene Expression Regulation Technologies
11.5. Technology Platforms for Developing / Delivering Gene Therapies

12. KEY THERAPEUTICS AREAS
12.1. Chapter Overview
12.2. Analysis by Therapeutic Area and Special Designation(s) Awarded
12.3. Oncological Disorders
12.3.1. Analysis by Target Indication
12.3.2. Analysis by Type of Vector Used
12.4. Nervous System Disorders
12.4.1. Analysis by Target Indication
12.4.2. Analysis by Type of Vector Used
12.5. Metabolic Disorders
12.5.1. Analysis by Target Indication
12.5.2. Analysis by Type of Vector Used
12.6. Ophthalmic Diseases
12.6.1. Analysis by Target Indication
12.6.2. Analysis by Type of Vector Used
12.7. Genetic Disorders
12.7.1. Analysis by Target Indication
12.7.2. Analysis by Type of Vector Used

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Gene Therapy Market: List of Patents 
13.2.1. Scope and Methodology
13.2.1.1. Analysis by Publication Year
13.2.1.2. Analysis by Publication Year and Type of Patent
13.2.1.3. Analysis by Geography 
13.2.1.4. Analysis by CPC Symbols 
13.2.1.5. Analysis by Emerging Focus Areas
13.2.1.6. Leading Players: Analysis by Number of Patents
13.2.1.7. Patent Benchmark Analysis
13.2.1.8. Patent Valuation Analysis
13.3. Gene Editing Market: List of Patents 
13.3.1. Scope and Methodology
13.3.1.1. Analysis by Publication Year
13.3.1.2. Analysis by Publication Year and Type of Patent
13.3.1.3. Analysis by Geography 
13.3.1.4. Analysis by CPC Symbols 
13.3.1.5. Analysis by Emerging Focus Areas
13.3.1.6. Leading Players: Analysis by Number of Patents
13.3.1.7. Patent Benchmark Analysis
13.3.1.8. Patent Valuation Analysis
13.4. Overall Intellectual Property Portfolio: Analysis by Type of Organization

14. MERGERS AND ACQUISITIONS
14.1. Chapter Overview
14.2. Merger and Acquisition Models
14.3. Gene Therapy Market: Mergers and Acquisitions
14.3.1. Analysis by Year of Agreement 
14.3.2. Analysis by Type of Agreement
14.3.3. Analysis by Geography 
14.3.3.1. Continent-wise Distribution
14.3.3.2. Intercontinental and Intracontinental Deals
14.3.3.3. Country-wise Distribution
14.3.4. Analysis by Key Value Drivers
14.3.4.1. Analysis by Key Value Drivers and Year of Acquisition
14.3.5. Analysis by Phase of Development of the Acquired Company’s Product
14.3.6. Analysis by Therapeutic Area

15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Types of Funding
15.3. Gene Therapy Market: Funding and Investment Analysis
15.3.1. Analysis by Number of Funding Instances
15.3.2. Analysis by Amount Invested
15.3.3. Analysis by Type of Funding
15.3.4. Analysis by Type of Funding and Year
15.3.5. Analysis of Amount Invested by Type of Gene Therapy 
15.3.6. Analysis of Amount Invested by Geography 
15.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
15.3.8. Key Investors: Analysis by Number of Funding Instances
15.3.9. Analysis by Phase of Development
15.3.10. Analysis by Therapeutic Area
15.4. Concluding Remarks

16. CLINICAL TRIAL ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Gene Therapy Market: Clinical Trial Analysis
16.3.1. Analysis by Trial Registration Year
16.3.2. Analysis by Trial Status
16.3.3. Analysis by Trial Phase
16.3.4. Analysis by Therapeutic Area
16.3.5. Analysis by Geography
16.3.6. Geographical Analysis by Trial Registration Year
16.3.7. Geographical Analysis by Trial Status
16.3.8. Geographical Analysis by Trial Status and Trial Phase
16.3.9. Geographical Analysis by Therapeutic Area
16.4. Analysis by Type of Sponsor
16.5. Analysis by Prominent Treatment Sites
16.6. Gene therapy Market: Analysis of Enrolled Patient Population
16.6.1. Analysis by Trial Registration Year
16.6.2. Analysis by Trial Status
16.6.3. Analysis by Trial Phase
16.6.4. Analysis by Therapeutic Area
16.6.5. Analysis by Location of Trial Site
16.6.6. Analysis by Trial Status and Location of Trial Site
16.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
16.6.8. Analysis by Therapeutic Area and Location of Trial Site
16.7. Concluding Remarks
16.7.1. Emerging Molecules to Watch
16.7.2. Most Important Trials to Watch

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Gene Therapy Market: Factors Contributing to the Price of Gene Therapies
17.3. Gene Therapy Market: Pricing Models
17.3.1. Based on Associated Product / Component Costs
17.3.2. Based on Competition
17.3.3. Based on Patient Segment
17.3.4. Based on Opinions of Industry Experts

18. BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES
18.1. Chapter Overview
18.2. Gene Therapy Market: List of Most Prominent Big Pharmaceutical Players 
18.2.1. Analysis by Therapeutic Area
18.2.2. Analysis by Type of Vector Used
18.2.3. Analysis by Therapeutic Approach
18.2.4. Analysis by Type of Gene Therapy
18.3. Other Big Pharma Players

19. DEMAND ANALYSIS
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Clinical Demand for Gene Therapies
19.4. Commercial Demand for Gene Therapies

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions and Forecast Methodology
20.4. Global Gene Therapy Market, 2020-2030
20.4.1. Gene Therapy Market: Analysis by Type of Gene Modification
20.4.2. Gene Therapy Market: Analysis by Type of Therapy
20.4.3. Gene Therapy Market: Analysis by Type of Vector Used
20.4.4. Gene Therapy Market: Analysis by Therapeutic Area
20.4.5. Gene Therapy Market: Analysis by Route of Administration
20.4.6. Gene Therapy Market: Analysis by Geography
20.5. Gene Therapy Market: Value Creation Analysis
20.6. Gene Therapy Market: Product-wise Sales Forecasts
20.6.1. Gendicine®
20.6.1.1. Target Patient Population
20.6.1.2. Sales Forecast
20.6.1.3. Net Present Value
20.6.1.4. Value Creation Analysis
20.6.2. Oncorine®
20.6.2.1. Target Patient Population
20.6.2.2. Sales Forecast
20.6.2.3. Net Present Value
20.6.2.4. Value Creation Analysis
20.6.3. Rexin-G®
20.6.3.1. Target Patient Population
20.6.3.2. Sales Forecast
20.6.3.3. Net Present Value
20.6.3.4. Value Creation Analysis
20.6.4. Neovasculgen®
20.6.4.1. Target Patient Population
20.6.4.2. Sales Forecast
20.6.4.3. Net Present Value
20.6.4.4. Value Creation Analysis
20.6.5. Strimvelis®
20.6.5.1. Target Patient Population
20.6.5.2. Sales Forecast
20.6.5.3. Net Present Value
20.6.5.4. Value Creation Analysis
20.6.6. Imlygic® 
20.6.6.1. Target Patient Population
20.6.6.2. Sales Forecast
20.6.6.3. Net Present Value
20.6.6.4. Value Creation Analysis
20.6.7. Luxturna™
20.6.7.1. Target Patient Population
20.6.7.2. Sales Forecast
20.6.7.3. Net Present Value
20.6.7.4. Value Creation Analysis
20.6.8. Zolgensma™
20.6.8.1. Target Patient Population
20.6.8.2. Sales Forecast
20.6.8.3. Net Present Value
20.6.8.4. Value Creation Analysis
20.6.9. Collategene®
20.6.9.1. Target Patient Population
20.6.9.2. Sales Forecast
20.6.9.3. Net Present Value
20.6.9.4. Value Creation Analysis
20.6.10. Zyntelgo™
20.6.10.1. Target Patient Population
20.6.10.2. Sales Forecast
20.6.10.3. Net Present Value
20.6.10.4. Value Creation Analysis
20.6.11. GS010
20.6.11.1. Target Patient Population
20.6.11.2. Sales Forecast
20.6.11.3. Net Present Value
20.6.11.4. Value Creation Analysis
20.6.12. PTC-AADC
20.6.12.1. Target Patient Population
20.6.12.2. Sales Forecast
20.6.12.3. Net Present Value
20.6.12.4. Value Creation Analysis
20.6.13. BMN 270
20.6.13.1. Target Patient Population
20.6.13.2. Sales Forecast
20.6.13.3. Net Present Value
20.6.13.4. Value Creation Analysis
20.6.14. rAd-IFN/Syn3
20.6.14.1. Target Patient Population
20.6.14.2. Sales Forecast
20.6.14.3. Net Present Value
20.6.14.4. Value Creation Analysis
20.6.15. TAVO™
20.6.15.1. Target Patient Population
20.6.15.2. Sales Forecast
20.6.15.3. Net Present Value
20.6.15.4. Value Creation Analysis
20.6.16. OTL-200
20.6.16.1. Target Patient Population
20.6.16.2. Sales Forecast
20.6.16.3. Net Present Value
20.6.16.4. Value Creation Analysis
20.6.17. EB-101
20.6.17.1. Target Patient Population
20.6.17.2. Sales Forecast
20.6.17.3. Net Present Value
20.6.17.4. Value Creation Analysis
20.6.18. ProstAtak®
20.6.18.1. Target Patient Population
20.6.18.2. Sales Forecast
20.6.18.3. Net Present Value
20.6.18.4. Value Creation Analysis
20.6.19. BIIB111
20.6.19.1. Target Patient Population
20.6.19.2. Sales Forecast
20.6.19.3. Net Present Value
20.6.19.4. Value Creation Analysis
20.6.20. LentiGlobin BB305®
20.6.20.1. Target Patient Population
20.6.20.2. Sales Forecast
20.6.20.3. Net Present Value
20.6.20.4. Value Creation Analysis
20.6.21. Lenti-D™
20.6.21.1. Target Patient Population
20.6.21.2. Sales Forecast
20.6.21.3. Net Present Value
20.6.21.4. Value Creation Analysis
20.6.22. FCX-007
20.6.22.1. Target Patient Population
20.6.22.2. Sales Forecast
20.6.22.3. Net Present Value
20.6.22.4. Value Creation Analysis
20.6.23. CG0070
20.6.23.1. Target Patient Population
20.6.23.2. Sales Forecast
20.6.23.3. Net Present Value
20.6.23.4. Value Creation Analysis
20.6.24. Vigil®
20.6.24.1. Target Patient Population
20.6.24.2. Sales Forecast
20.6.24.3. Net Present Value
20.6.24.4. Value Creation Analysis
20.6.25. VM202
20.6.25.1. Target Patient Population
20.6.25.2. Sales Forecast
20.6.25.3. Net Present Value
20.6.25.4. Value Creation Analysis
20.6.26. VGX-3100
20.6.26.1. Target Patient Population
20.6.26.2. Sales Forecast
20.6. 26.3. Net Present Value
20.6.26.4. Value Creation Analysis
20.6.27. Invossa™
20.6.27.1. Target Patient Population
20.6.27.2. Sales Forecast
20.6.27.3. Net Present Value
20.6.27.4. Value Creation Analysis
20.6.28. KB103
20.6.28.1. Target Patient Population
20.6.28.2. Sales Forecast
20.6.28.3. Net Present Value
20.6.28.4. Value Creation Analysis
20.6.29. PF-06939926
20.6.29.1. Target Patient Population
20.6.29.2. Sales Forecast
20.6.29.3. Net Present Value
20.6.29.4. Value Creation Analysis
20.6.30. PF-06838435
20.6.30.1. Target Patient Population
20.6.30.2. Sales Forecast
20.6.30.3. Net Present Value
20.6.30.4. Value Creation Analysis
20.6.31. PF-07055480
20.6.31.1. Target Patient Population
20.6.31.2. Sales Forecast
20.6.31.3. Net Present Value
20.6.31.4. Value Creation Analysis
20.6.32. SPK-8011
20.6.32.1. Target Patient Population
20.6.32.2. Sales Forecast
20.6.32.3. Net Present Value
20.6.32.4. Value Creation Analysis
20.6.33. AMT-061
20.6.33.1. Target Patient Population
20.6.33.2. Sales Forecast
20.6.33.3. Net Present Value
20.6.33.4. Value Creation Analysis
20.6.34. VB-111
20.6.34.1. Target Patient Population
20.6.34.2. Sales Forecast
20.6.34.3. Net Present Value
20.6.34.4. Value Creation Analysis
20.6.35. OTL-101
20.6.35.1. Target Patient Population
20.6.35.2. Sales Forecast
20.6.35.3. Net Present Value
20.6.35.4. Value Creation Analysis
20.6.36. BIIB112
20.6.36.1. Target Patient Population
20.6.36.2. Sales Forecast
20.6.36.3. Net Present Value
20.6.36.4. Value Creation Analysis
20.6.37. FLT180a
20.6.37.1. Target Patient Population
20.6.37.2. Sales Forecast
20.6.37.3. Net Present Value
20.6.37.4. Value Creation Analysis
20.6.38. LYS-SAF302
20.6.38.1. Target Patient Population
20.6.38.2. Sales Forecast
20.6.38.3. Net Present Value
20.6.38.4. Value Creation Analysis
20.6.39. NFS-01
20.6.39.1. Target Patient Population
20.6.39.2. Sales Forecast
20.6.39.3. Net Present Value
20.6.39.4. Value Creation Analysis
20.6.40. OTL-103
20.6.40.1. Target Patient Population
20.6.40.2. Sales Forecast
20.6.40.3. Net Present Value
20.6.40.4. Value Creation Analysis

21. VECTOR MANUFACTURING
21.1. Chapter Overview
21.2. Overview of Viral Vector Manufacturing
21.3. Viral Vector Manufacturing Processes
21.3.1. Mode of Vector Production
21.3.2. Adherent and Suspension Cultures
21.3.3. Unit and Parallel Processes
21.3.4. Cell Culture Systems for Production of Viral Vectors
21.3.5. Culture Media Specifications 
21.4. Bioprocessing of Viral Vectors
21.4.1. Adeno-associated Viral Vector Production
21.4.2. Adenoviral Vector Production
21.4.3. Lentiviral Vector Production
21.4.4. ? -Retroviral Vector Production
21.5. Challenges Associated with Vector Manufacturing
21.6. Companies Offering Contract Services for Viral and Plasmid Vectors

22. CASE STUDY: GENE THERAPY SUPPLY CHAIN
22.1. Chapter Overview
22.2. Overview of the Gene Therapy Supply Chain
22.3. Implementation of Supply Chain Models
22.4. Logistics Associated with Gene Therapies
22.4.1. Autologous and Allogeneic Therapies
22.5. Regulatory Supply Chain Across the Globe
22.6. Challenges Associated with Gene Therapy Supply Chain
22.7. Optimizing Cell and Advanced Therapies Supply Chain Management
22.7.1. Enterprise Manufacturing Systems
22.7.2. Laboratory Information Management Systems
22.7.3. Inventory Management Systems
22.7.4. Quality Management Systems
22.7.5. Logistics Management Systems
22.7.6. Patient Management Systems
22.7.7. Electronic Clinical Outcome Assessments Systems
22.7.8. Supply Chain Orchestration Platforms
22.8. Recent Developments and Upcoming Trends

23. CONCLUSION

24. INTERVIEW TRANSCRIPTS
24.1. Chapter Overview
24.2. Adam Rogers, CEO, Hemera Biosciences 
24.3. Al Hawkins, CEO, Milo Biotechnology 
24.4. Buel Dan Rodgers, Founder and CEO, AAVogen 
24.5. Christopher Reinhard, CEO and Chairman, Gene Therapeutics (previously known as Cardium Therapeutics)
24.6. Michael Tripletti, CEO, Myonexus Therapeutics
24.7. Robert Jan Lamers, CEO, Arthrogen 
24.8. Ryo Kubota, CEO, Chairman and President, Acucela
24.9. Tom Wilton, CBO, LogicBio Therapeutics
24.10. Jeffrey Hung, CCO, Vigene Biosciences 
24.11. Cedric Szpirer, Executive & Scientific Director, Delphi Genetics 
24.12. Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager, PlasmidFactory 
24.13. Molly Cameron, Corporate Communications Manager, Orchard Therapeutics

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • 4BIO Capital
  • 4D Molecular Therapeutics
  • 5AM Ventures
  • AavantiBio
  • aaVective
  • AAVogen
  • AbbVie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • Abintus Bio
  • Adage Capital Management
  • Adrenas Therapeutics
  • Advantagene (also known as Candel Therapeutics)
  • Advaxis
  • Adverum Biotechnologies
  • Aevitas Therapeutics
  • Affinia Therapeutics
  • Agent Capital
  • Agilis Biotherapeutics
  • AGTC
  • Aisling Capital
  • AJU IB Investment
  • Akouos
  • Alexandria Venture Investments
  • Allergan
  • Ally Bridge Group
  • Alpha Holdings
  • AlphaVax
  • Altheia Science
  • Altitude Life Science Ventures
  • Amarna Therapeutics
  • Ambulero
  • American Gene Technologies™
  • Amgen
  • Amicus Therapeutics
  • Amplo
  • Anaeropharma Science
  • AnGes
  • Angionetics
  • Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
  • ApolloBio
  • Apple Tree Partners
  • ARCH Venture Partners
  • Arix Bioscience
  • Arkin Bio Ventures
  • ArrowMark Partners
  • Arthrogen
  • ARTIS Ventures
  • Aruvant Sciences
  • ASC Therapeutics
  • Asia Alpha
  • Asklepios BioPharmaceutical (AskBio)
  • Aspa Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • Atsena Therapeutics
  • Audentes Therapeutics
  • Audition Therapeutics
  • Auriga Partners
  • Avalanche Biotechnologies
  • AVROBIO
  • Axovant Gene Therapies
  • Baillie Gifford
  • Bain Capital Life Sciences
  • Baldota Group
  • Bamboo Therapeutics
  • Bayer
  • Beam Therapeutics
  • Berkeley Catalyst Fund
  • Biogen
  • BioInvent International
  • BioMarin Pharmaceutical
  • Biomatics Capital 
  • Bionic Sight
  • BioVec Pharma
  • Bioverativ (a Sanofi company)
  • Blue Bear Ventures
  • bluebird bio
  • BlueWater Angels
  • Boehringer Ingelheim
  • Boxer Capital
  • Bpifrance 
  • Brace Pharma Capital
  • Brain Neurotherapy Bio
  • BrainVectis
  • Breakout Ventures
  • BridgeBio
  • Bristol-Myers Squibb
  • Brookside Capital
  • BVF Partners
  • California Institute for Regenerative Medicine
  • Calimmune
  • Cambridge Enterprise
  • Cambridge Gene Therapy
  • Cambridge Innovation Capital
  • Cancer Research Institute
  • CapDecisif Management
  • Cardiogen Sciences
  • Carmine Therapeutics
  • Casdin Capital
  • Case Western Reserve University 
  • Castle Creek Biosciences
  • Catalyst Biosciences
  • CavoGene LifeSciences
  • Celenex (Nationwide Children’s Hospital Spin Out)
  • CellGenTech
  • Celsion
  • CG Oncology
  • Chiba University
  • Children’s Medical Research Foundation
  • Children’s Oncology Group
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • CODA Biotherapeutics
  • Codexis
  • Columbia University
  • Columbus Venture Partners
  • CombiGene
  • Consort Medical
  • Copernicus Therapeutics
  • Cormorant Asset Management
  • Cowen Group
  • Cowen Private Investments
  • CRISPR Therapeutics
  • CSL Behring
  • CureDuchenne Ventures
  • Cynvec
  • Cyprium Therapeutics
  • Cystic Fibrosis Foundation Therapeutics
  • DARPA
  • Deerfield Management
  • DEFTA Partners
  • Denovo Biopharma
  • Dexcel Pharma
  • Dimension Therapeutics
  • DiNAQOR
  • Discovery Genomics
  • DNAlite Therapeutics
  • DNAtrix
  • Driehaus Capital Management
  • Duke University
  • Dyno Therapeutics
  • EB Medical Research Foundation
  • EcoR1 Capital
  • Editas Medicine
  • Edmond de Rothschild Investment Partners
  • Eight Roads Ventures
  • Emendo Biotherapeutics
  • Emory University
  • Emrys Bio
  • Encoded Therapeutics
  • Endsulin
  • Enochian BioSciences
  • Entos Pharmaceuticals
  • Epeius Biotechnologies
  • EPS Holdings
  • Errant Gene Therapeutics
  • Esco Ventures
  • ESTEVE
  • European Innovation Council Accelerator
  • European Investment Bank
  • Eventide Asset Management
  • Evotec
  • Excision BioTherapeutics
  • Exegenesis Bio
  • Exonics Therapeutics
  • Expression Therapeutics
  • ExSight Capital
  • Eyevensys
  • FerGene (Ferring Pharmaceuticals subsidiary)
  • FF Science
  • Fibrocell Science
  • Fidelity Management & Research Company
  • Flagship Pioneering
  • Flash Therapeutics
  • Flerie Invest AB
  • Flexion Therapeutics
  • Fondation Sanfilippo Suisse
  • Foresite Capital
  • Forge Biologics
  • Forte Biosciences
  • Fosun Capital
  • FoxKiser
  • F-Prime Capital
  • Franklin Templeton Investments
  • Frazier Healthcare Partners
  • Freeline Therapeutics
  • Friedreich’s Ataxia Research Alliance
  • Fund+
  • Fundación Sanfilippo B
  • Galia Gestion
  • Gemini Therapeutics
  • Genable Technologies
  • Gene Therapy Research Institution
  • GeneCure Biotechnologies
  • Genelux
  • GeneMedicine
  • GeneOne Life Science
  • GeneQuine Biotherapeutics
  • Generation Bio
  • Genespire
  • Genethon
  • GeneTx
  • Genexine
  • Genprex
  • GenSight Biologics
  • GenVec 
  • Ghost Tree Capital Group
  • GO CAPITAL
  • GOFAR
  • GOG Foundation
  • Google Ventures
  • Gradalis
  • Green Cross Holdings
  • GSK
  • Gyroscope Therapeutics
  • Handl Therapeutics
  • Harvard University
  • Hatteras Venture Partners
  • Hayfin Capital Management
  • HBM Healthcare Investments
  • HealthCap
  • Helixmith
  • Hemera Biosciences
  • Herantis Pharma
  • Hiroshima Venture Capital
  • Histogenics
  • Holostem Terapie Avanzate
  • Homology Medicines
  • HORAMA
  • Horizon Technology Finance
  • Hovione Scientia
  • Huapont Life Sciences
  • Human Stem Cells Institute PJSC (HSCI)
  • Idinvest Partners
  • Ikarovec
  • Illumina Ventures
  • Ilya Pharma
  • Immusoft
  • Imperial Innovations
  • Innovate UK
  • Innovation Network Corporation of Japan
  • Inotek Pharmaceuticals
  • Inovio Pharmaceuticals
  • Inserm Transfert
  • Institute of Myology
  • Intellia Therapeutics
  • Intrexon
  • Invus
  • Israel Innovation Authority
  • IVERIC bio
  • Janssen Pharmaceuticals
  • Janus Capital Management
  • Jennison Associates
  • Johnson & Johnson Development
  • Juda Capital
  • K2 Venture Capital
  • Kiwoom Securities
  • Kleiner Perkins
  • Kodikaz Therapeutic Solutions
  • Kolon TissueGene
  • Korea Investment Partners
  • Kriya Therapeutics
  • Krystal Biotech
  • Kubota Vision
  • Kurma Partners
  • Kyorin Pharmaceutical
  • Lacerta Therapeutics
  • Leerink Partners
  • Legend Capital
  • Leiden University Medical Center 
  • Lentistem® Biotech
  • LEXEO Therapeutics
  • LifeArc
  • Lilly Asia Ventures
  • Lime Asset Management
  • Limelight Bio
  • Lipigon Pharmaceuticals
  • LogicBio Therapeutics
  • Lokon Pharma
  • Longitude Capital
  • Ludwig Cancer Research
  • Lundbeckfonden Ventures
  • Lysogene
  • Mangrove Partners
  • Maryland Technology Development
  • Matrix Capital Management
  • Maverick Ventures
  • Medison Ventures
  • MeiraGTx
  • Memorial Sloan Kettering Cancer Center
  • Mercia Technologies
  • Merck
  • MERITZ Securities
  • Mesa Verde Venture Partners
  • Michigan Economic Development
  • MidCap Financial
  • Milo Biotechnology
  • Mirae Asset Financial Group
  • Mita Securities
  • Mitsubishi Tanabe Pharma
  • Mitsubishi UFJ Asset Management
  • Momotaro-Gene
  • MultiVir
  • Muscular Dystrophy Association
  • Mustang Bio
  • Myonexus Therapeutics
  • Myosana Therapeutics
  • NanoCor Therapeutics
  • Nanogenic Solutions
  • Narya Capital
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Health
  • National MPS Society
  • Nationwide Children’s Hospital
  • Navega Therapeutics
  • NeoMed
  • Nerveda
  • Netherlands Enterprise Agency
  • NeuExcell Therapeutics
  • Neuracle Genetics
  • Neurimmune
  • Neurocrine Biosciences
  • Neurogene
  • Neurophth Therapeutics
  • New Energy and Industrial Technology Development Organization
  • New Enterprise Associates
  • New Leaf Venture Partners
  • Nightstar Therapeutics
  • Ninevah Therapeutics
  • Noga Therapeutics
  • Northpond Ventures
  • Novartis
  • Novo Holdings
  • Novo Nordisk
  • Oberland Capital
  • Ocugen
  • Odylia Therapeutics
  • Okayama University
  • Omega Funds
  • Omnes Capital
  • Oncolys BioPharma
  • Onconetics Pharmaceuticals
  • Oncos Therapeutics
  • OncoSec Medical
  • OncoSenX
  • OrbiMed
  • Orbit Biomedical
  • ORCA Therapeutics
  • Orchard Therapeutics
  • ORI Capital
  • Osage University Partners
  • Otonomy
  • Oxford BioMedica
  • Oxford Finance
  • Oxular
  • Panmure Gordon
  • Paragon Biosciences
  • Parker Institute for Cancer Immunotherapy
  • Partners Innovation Fund
  • Passage Bio
  • Pattern Bioscience
  • Pavilion Capital
  • PBM Capital
  • Pentwater Capital Management
  • Perceptive Advisors
  • PeriphaGen
  • Perseverance Capital Management
  • Pfizer
  • Pharmakon Advisors
  • Phoenix Nest
  • PhorMed
  • Pivotal bioVenture Partners
  • PlasmaTech Biopharmaceuticals
  • Pontifax Venture Capital
  • POSCO Capital
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Prevail Therapeutics
  • Progenics Pharmaceuticals
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • RA Capital Management
  • RBV Capital
  • Red Sanfilippo Foundation
  • Redbiotec
  • Redmile Group
  • Redpin Therapeutics
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • Renova Therapeutics
  • Rentschler Biopharma
  • Rev1 Ventures
  • Reyon Pharmaceutical
  • Ridgeback Capital Investments
  • Ring Therapeutics
  • Roche
  • Rock Springs Capital
  • Rocket Pharmaceuticals
  • Roswell Park Comprehensive Cancer Center
  • RoverMed BioSciences
  • RTW Investments
  • Ryboquin
  • Samsara BioCapital
  • Sanfilippo Children’s Foundation
  • Sangamo Therapeutics
  • Sanofi
  • Sanofi Genzyme 
  • Santen Pharmaceutical
  • Sarepta Therapeutics
  • Scancell
  • SDL Ventures
  • Seattle Children’s Research Institute
  • Selecta Biosciences
  • Sequoia Capital China
  • Seraph Research Institute
  • Seventure Partners
  • Sham Innovation Sante
  • Shanghai Sunway Biotech
  • Shenzhen Qianhai Taxus
  • Shinhan Capital
  • Shinsei Corporate Investment
  • Shire
  • Sibiono GeneTech
  • SillaJen
  • Sofinnova Ventures
  • Solid Biosciences
  • Sorrento Therapeutics
  • SOSV
  • SOTIO
  • Spark Therapeutics
  • Sphera Global Healthcare Fund
  • Spirovant Sciences
  • SR-Tiget
  • St. Jude Children’s Research Hospital
  • Stanford University
  • StrideBio
  • Surveyor Capital
  • SwanBio Therapeutics
  • Syncona
  • Synpromics
  • T. Rowe Price
  • Takeda Pharmaceutical
  • Tamid Bio
  • Target ALS Foundation
  • Targovax
  • Taysha Gene Therapies
  • Temasek 
  • Tenaya Therapeutics
  • The Army Small Business Innovation Research
  • The Column Group
  • TheraBiologics
  • Theravectys
  • TNK Therapeutics
  • Tocagen
  • Tolerion
  • TPG Capital
  • Transgene
  • Transhuman Capital
  • Trucode Gene Repair
  • UCL Technology Fund
  • UK Cystic Fibrosis Gene Therapy Consortium
  • Ultragenyx Pharmaceutical
  • uniQure Biopharma
  • Universitat Autònoma de Barcelona (UAB)
  • University College London
  • University Hospitals Cleveland Medical Center
  • University of California San Diego School of Medicine
  • University of Florida
  • University of Massachusetts
  • University of North Carolina at Chapel Hill
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Washington
  • Urovant Sciences
  • Valor Equity Partners
  • V-Bio Ventures
  • VBL Therapeutics
  • VCN Biosciences
  • Vectalys
  • venBio
  • Venrock
  • Versant Ventures
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • Vida Ventures
  • ViGeneron (spin-off of the Ludwig-Maximilians-University)
  • Viking Global Investors
  • Virttu Biologics
  • Vivet Therapeutics
  • Vivo Capital
  • Voyager Therapeutics
  • VREX Therapeutics
  • Washington Research Foundation
  • Washington State University's Office of Commercialization
  • Waverly Capital
  • Weill Cornell Medicine
  • Wellcome Trust
  • Whitesun Healthcare Ventures
  • WI Harper Group
  • Wize Pharma
  • Woodford Investment Management
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • XyloCor Therapeutics
  • Ysios Capital
  • Ziopharm Oncology
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll